GVK Bio partners US firm

Hyderabad-based drug discovery research and development firm (GVK Bio) has entered into a collaboration agreement with US-based Endo Pharmaceuticals focused on discovering novel small molecules targeting a protein.

As per the agreement, GVK Bio will use its discovery expertise to deliver a clinical candidate and Endo will develop and commercialise the product arising out of this collaboration. The collaboration arose out of a newly-launched concept at GVK Bio named Early Discovery Assets (EDA).

image
Business Standard
177 22
Business Standard

GVK Bio partners US firm

BS Reporter  |  Chennai 



Hyderabad-based drug discovery research and development firm (GVK Bio) has entered into a collaboration agreement with US-based Endo Pharmaceuticals focused on discovering novel small molecules targeting a protein.

As per the agreement, GVK Bio will use its discovery expertise to deliver a clinical candidate and Endo will develop and commercialise the product arising out of this collaboration. The collaboration arose out of a newly-launched concept at GVK Bio named Early Discovery Assets (EDA).

RECOMMENDED FOR YOU

GVK Bio partners US firm

Hyderabad-based drug discovery research and development firm GVK Biosciences (GVK Bio) has entered into a collaboration agreement with US-based Endo Pharmaceuticals focused on discovering novel small molecules targeting a protein.

Hyderabad-based drug discovery research and development firm (GVK Bio) has entered into a collaboration agreement with US-based Endo Pharmaceuticals focused on discovering novel small molecules targeting a protein.

As per the agreement, GVK Bio will use its discovery expertise to deliver a clinical candidate and Endo will develop and commercialise the product arising out of this collaboration. The collaboration arose out of a newly-launched concept at GVK Bio named Early Discovery Assets (EDA).

image
Business Standard
177 22
Widgets Magazine

More News

  • Vishal Sikka Infosys to give clearer picture on guidance post Q2
  • Gammon Infra shares down nearly 5% after Q1 results Gammon Infra shares down nearly 5% after Q1 results
Widgets Magazine
Widgets Magazine

Upgrade To Premium Services

Welcome User

Business Standard is happy to inform you of the launch of "Business Standard Premium Services"

As a premium subscriber you get an across device unfettered access to a range of services which include:

  • Access Exclusive content - articles, features & opinion pieces
  • Weekly Industry/Genre specific newsletters - Choose multiple industries/genres
  • Access to 17 plus years of content archives
  • Set Stock price alerts for your portfolio and watch list and get them delivered to your e-mail box
  • End of day news alerts on 5 companies (via email)
  • NEW: Get seamless access to WSJ.com at a great price. No additional sign-up required.
 

Premium Services

In Partnership with

 

Dear Guest,

 

Welcome to the premium services of Business Standard brought to you courtesy FIS.
Kindly visit the Manage my subscription page to discover the benefits of this programme.

Enjoy Reading!
Team Business Standard